Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNMX
CUSIPN/A
Phone610-254-4201
Debt
Debt-to-Equity RatioN/A
Current Ratio5.78
Quick Ratio5.78
Price-To-Earnings
Trailing P/E Ratio-1.43
Forward P/E Ratio-1.97
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.52 per share
Price / Book2.27
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-34,710,000.00
Net MarginsN/A
Return on Equity-160.09%
Return on Assets-127.64%
Miscellaneous
Employees17
Outstanding Shares59,340,000
Aevi Genomic Medicine (NASDAQ:GNMX) Frequently Asked Questions
What is Aevi Genomic Medicine's stock symbol?
Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."
How were Aevi Genomic Medicine's earnings last quarter?
Aevi Genomic Medicine Inc (NASDAQ:GNMX) released its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.01. View Aevi Genomic Medicine's Earnings History.
What price target have analysts set for GNMX?
2 brokerages have issued twelve-month price objectives for Aevi Genomic Medicine's stock. Their forecasts range from $1.50 to $7.00. On average, they anticipate Aevi Genomic Medicine's share price to reach $4.25 in the next twelve months. View Analyst Ratings for Aevi Genomic Medicine.
Who are some of Aevi Genomic Medicine's key competitors?
Some companies that are related to Aevi Genomic Medicine include Allena Pharmaceuticals (ALNA), Jounce Therapeutics (JNCE), Arsanis (ASNS), Agenus (AGEN), Nantkwest (NK), ADMA Biologics (ADMA), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Organovo (ONVO), Krystal Biotech (KRYS), Eiger Biopharmaceuticals (EIGR), Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Cidara Therapeutics (CDTX) and Brainstorm Cell Therapeutics (BCLI).
Who are Aevi Genomic Medicine's key executives?
Aevi Genomic Medicine's management team includes the folowing people:
- Mr. Michael F. Cola, CEO, Pres & Director (Age 58)
- Mr. Brian D. Piper, CFO & Corp. Sec. (Age 46)
- Dr. Garry A. Neil, Chief Scientific Officer (Age 64)
- Ms. Colleen Anderson, VP of Clinical Operations
- Dr. Rick Couch, VP of Chemistry, Manufacturing & Controls
Has Aevi Genomic Medicine been receiving favorable news coverage?
News articles about GNMX stock have been trending somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aevi Genomic Medicine earned a news sentiment score of 0.08 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 45.95 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Aevi Genomic Medicine's major shareholders?
Aevi Genomic Medicine's stock is owned by many different of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (0.17%). Company insiders that own Aevi Genomic Medicine stock include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Institutional Ownership Trends for Aevi Genomic Medicine.
Which major investors are buying Aevi Genomic Medicine stock?
GNMX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have bought Aevi Genomic Medicine stock in the last two years include Garry Arthur Neil, Michael F Cola, Philip R Harper and Sol J Barer. View Insider Buying and Selling for Aevi Genomic Medicine.
How do I buy shares of Aevi Genomic Medicine?
Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aevi Genomic Medicine's stock price today?
One share of GNMX stock can currently be purchased for approximately $1.18.
How big of a company is Aevi Genomic Medicine?
Aevi Genomic Medicine has a market capitalization of $71.20 million. The biotechnology company earns $-34,710,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Aevi Genomic Medicine employs 17 workers across the globe.
How can I contact Aevi Genomic Medicine?
Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]
MarketBeat Community Rating for Aevi Genomic Medicine (GNMX)
MarketBeat's community ratings are surveys of what our community members think about Aevi Genomic Medicine and other stocks. Vote "Outperform" if you believe GNMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
